Clinical Outcomes of Cardiovascular Disease
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Cardiovascular Diseases, Heart Failure, Coronary Artery Disease. Basic parameters: 18 years — 80 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Clinical Outcomes of Cardiovascular Disease: a Prospective Cohort Study
Overview
This study is a prospective, single center cohort study that primarily registers the clinical characteristics, outcomes, and influencing factors of patients with different types of cardiovascular diseases. Evaluate multiple examination indicators of patients at baseline, 1 year and longer, and follow up on the incidence of major cardiovascular and cerebrovascular adverse events, heart failure readmission, death, and other endpoint events.
Detailed description
This study is a prospective, single center cohort study that primarily registers the clinical characteristics, outcomes, and influencing factors of patients with different types of cardiovascular diseases. Mainly including coronary heart disease, cardiomyopathy, hypertension, heart failure and other diseases, multiple examination indicators are evaluated for patients at baseline, 1 year and longer periods of time. The primary endpoints for coronary heart disease are all-cause mortality, cardiogenic death, non fatal myocardial infarction, hospitalization for heart failure, and major cardiovascular adverse events. The primary endpoints for cardiomyopathy are all-cause mortality, cardiogenic death, hospitalization for heart failure, and major cardiovascular adverse events. The primary endpoints for hypertension are stroke, all-cause mortality, cardiogenic death, hospitalization for heart failure, and major cardiovascular and cerebrovascular adverse events. The primary endpoints for heart failure are all-cause mortality, cardiogenic death, readmission for heart failure, and major cardiovascular adverse events.
Primary outcome measures
- All cause death [Time frame: 1 year.]
- Cardiac death [Time frame: 1 year.]
- Main adverse cardiovascular events（MACE） [Time frame: 1 year.]
- Heart failure [Time frame: 1 year.]
- Stroke [Time frame: 1 year.]
Secondary outcome measures (7)
- Main adverse cardiovascular and cerebrovascular events（MACCE） [Time frame: 1 year.]
- Main adverse cardiovascular and cerebrovascular events（MACCE） [Time frame: 3 years.]
- All cause death [Time frame: 3 years.]
- Cardiac death [Time frame: 3 years.]
- Main adverse cardiovascular events（MACE） [Time frame: 3 years.]
- Heart failure [Time frame: 3 years.]
- Stroke [Time frame: 3 years.]
Eligibility criteria
Inclusion criteria
- Coronary heart disease According to coronary angiography and coronary CTA, at least one coronary artery has a degree of stenosis greater than 50%.
- Hypertension Hypertension is defined as office systolic blood pressure is ≥ 140mmHg and/or the diastolic blood pressure is ≥ 90mmHg without the use of antihypertensive drugs.
- Heart failure There is a clear history of organic heart disease, clinical symptoms and signs of heart failure, and objective evidence of heart failure.
- Cardiomyopathy Including defined dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy, etc.
- Able to sign informed consent form.
Exclusion criteria
- Age<18 years old, or>80 years old.
- Patients with various malignant tumors.
- Liver dysfunction (defined as ALT or total bilirubin greater than three times the upper normal limit).
- Renal insufficiency (defined as blood creatinine exceeding 1.5 times the upper normal limit).
- Those who have participated in other clinical studies within the past three months.
- Individuals without legal capacity or with limited legal capacity.
- Any situation where the researcher deems it unsuitable to participate in the clinical study.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- The First Affiliated Hospital of Xinjiang Medicial University — Ürümqi
Identifiers
NCT: NCT06459934 · 20240606